Brief: Metavia Reports Positive Statistically Significant Results From Its Phase 1B Clinical Trial Of Da-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss And Favorable Safety Profile
05/01/2026 14:09
MetaVia Inc MTVA.O: METAVIA REPORTS POSITIVE STATISTICALLY SIGNIFICANT RESULTS FROM ITS PHASE 1B CLINICAL TRIAL OF DA-1726 IN METABOLIC DISEASE - DEMONSTRATING STRONG GLYCEMIC RESPONSE, SIGNIFICANT DIRECT HEPATIC EFFECTS, ROBUST WEIGHT LOSS AND FAVORABLE SAFETY PROFILE METAVIA INC - 9.8 CM WAIST CIRCUMFERENCE REDUCTION AT DAY 54 IN STUDY METAVIA INC - 23.7% REDUCTION IN LIVER STIFFNESS BY DAY 54 IN STUDY METAVIA INC - 12.3 MG/DL FASTED GLUCOSE REDUCTION BY DAY 54 IN STUDY METAVIA INC - 9.1% WEIGHT LOSS (21.2 LBS) BY DAY 54 IN STUDY Source text: ID:nPn6Kvghwa Further company coverage: MTVA.O
Recent news on MetaVia
See all newsMetaVia Inc reports results for the quarter ended June 30 - Earnings Summary
MetaVia Q2 net loss widens on higher R&D spending
MetaVia Inc expected to post a loss of 82 cents a share - Earnings Preview
Brief: Biostem Technologies Announces Appointment Of Three New Members To Its Board Of Directors
MetaVia Q1 net loss widens slightly as expenses rise